News & Updates

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024 byStephen Padilla

Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024